RSS-Feed abonnieren
DOI: 10.1055/s-0042-1742292
Polycystic Ovary Syndrome in Adolescence: Challenges in Diagnosis and Management
Síndrome do ovário policístico na adolescência: Desafios no diagnóstico e tratamentoAbstract
Diagnosing polycystic ovary syndrome (PCOS) during adolescence is challenging since normal pubertal development overlap typical features of this syndrome. The authors aim to summarize the existing evidence concerning PCOS in adolescence, particularly its diagnostic criteria and therapeutic options. A search throughout medical databases such as PubMed and MedScape was performed. Diagnostic criteria include irregular menstrual cycles according to time postmenarche and evidence of clinical hyperandrogenism and/or biochemical hyperandrogenism, provided other causes have been excluded. Polycystic ovarian morphology ought not to be used as a diagnostic criterion. Treatment should target manifestations and/or comorbidities, even in the absence of a definite diagnosis. Lifestyle interventions are the first-line treatment. Combined oral contraceptives, metformin or antiandrogens may also be considered as adjuvants. Screening for PCOS in adolescence is crucial as it allows an early intervention on the symptoms and comorbidities presented leading to better long-term reproductive and metabolic outcomes.
Resumo
Diagnosticar a síndrome do ovário policístico (SOP) durante a adolescência é um desafio, uma vez que o desenvolvimento puberal normal se sobrepõe às características típicas desta síndrome. Os autores têm por objetivo resumir as evidências existentes sobre a SOP na adolescência, particularmente seus critérios diagnósticos e opções terapêuticas. Uma pesquisa em bases de dados médicas como PubMed e MedScape foi realizada. Os critérios de diagnóstico incluem ciclos menstruais irregulares de acordo com o tempo pós-menarca e evidência de hiperandrogenismo clínico e/ou hiperandrogenismo bioquímico, após exclusão de outras causas. A morfologia policística dos ovários não deve ser usada como um critério diagnóstico. O tratamento deve ser direcionado às manifestações e/ou comorbilidades, mesmo na ausência de um diagnóstico definitivo. As intervenções no estilo de vida são o tratamento de primeira linha. Contraceptivos orais combinados, metformina ou antiandrogênios também podem ser considerados como adjuvantes. O rastreamento da SOP na adolescência é fundamental, pois permite uma intervenção precoce ao nível dos sintomas e comorbilidades presentes levando a melhores resultados reprodutivos e metabólicos a longo prazo.
Publikationsverlauf
Eingereicht: 03. März 2021
Angenommen: 03. November 2021
Artikel online veröffentlicht:
27. Mai 2022
© 2022. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 Le TN, Wickham EP, Nestler JE. Insulin sensitizers in adolescents with polycystic ovary syndrome. Minerva Pediatr 2017; 69 (05) 434-443 DOI: 10.23736/S0026-4946.17.04976-3.
- 2 Witchel SF, Teede HJ, Peña AS. Curtailing PCOS. Pediatr Res 2020; 87 (02) 353-361 DOI: 10.1038/s41390-019-0615-1.
- 3 Ibáñez L, Oberfield SE, Witchel S, Auchus RJ, Chang RJ, Codner E. et al. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr 2017; 88 (06) 371-395 DOI: 10.1159/000479371.
- 4 Fitzgerald S, DiVasta A, Gooding H. An update on PCOS in adolescents. Curr Opin Pediatr 2018; 30 (04) 459-465 DOI: 10.1097/MOP.0000000000000636.
- 5 Trent M, Gordon CM. Diagnosis and management of polycystic ovary syndrome in adolescents. Pediatrics 2020; 145 (Suppl. 02) S210-S218 DOI: 10.1542/peds.2019-2056J.
- 6 Soares-Jr JM, Sá MFS, Baracat EC. New criteria for the clinical diagnosis of hyperandrogenism in polycystic ovarian syndrome and the risk of overdiagnosis. Rev Bras Ginecol Obstet 2019; 41 (06) 361-362 DOI: 10.1055/s-0039-1693530.
- 7 Spritzer PM, Motta AB. Adolescence and polycystic ovary syndrome: current concepts on diagnosis and treatment. Int J Clin Pract 2015; 69 (11) 1236-1246 DOI: 10.1111/ijcp.12719.
- 8 Ramezani Tehrani F, Amiri M. Polycystic ovary syndrome in adolescents: challenges in diagnosis and treatment. Int J Endocrinol Metab 2019; 17 (03) e91554 DOI: 10.5812/ijem.91554.
- 9 Rosenfield RL. Perspectives on the international recommendations for the diagnosis and treatment of polycystic ovary syndrome in adolescence. J Pediatr Adolesc Gynecol 2020; 33 (05) 445-447 DOI: 10.1016/j.jpag.2020.06.017.
- 10 DiVall S, Merjaneh L. Adolescent polycystic ovary syndrome: an update. Pediatr Ann 2019; 48 (08) e304-e310
- 11 Kostopoulou E, Anagnostis P, Bosdou JK, Spiliotis BE, Goulis DG. Polycystic ovary syndrome in adolescents: pitfalls in diagnosis and management. Curr Obes Rep 2020; 9 (03) 193-203 DOI: 10.1007/s13679-020-00388-9.
- 12 Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc 2019; 3 (08) 1545-1573 DOI: 10.1210/js.2019-00078.
- 13 Akgül S, Düzçeker Y, Kanbur N, Derman O. Do different diagnostic criteria impact polycystic ovary syndrome diagnosis for adolescents?. J Pediatr Adolesc Gynecol 2018; 31 (03) 258-262 DOI: 10.1016/j.jpag.2017.12.002.
- 14 Vassalou H, Sotiraki M, Michala L. PCOS diagnosis in adolescents: the timeline of a controversy in a systematic review. J Pediatr Endocrinol Metab 2019; 32 (06) 549-559 DOI: 10.1515/jpem-2019-0024.
- 15 Akgül S, Bonny AE. Metabolic syndrome in adolescents with polycystic ovary syndrome: prevalence on the basis of different diagnostic criteria. J Pediatr Adolesc Gynecol 2019; 32 (04) 383-387 DOI: 10.1016/j.jpag.2019.01.006.
- 16 Peña AS, Witchel SF, Hoeger KM, Oberfield SE, Vogiatzi MG, Misso M. et al. Adolescent polycystic ovary syndrome according to the international evidence-based guideline. BMC Med 2020; 18 (01) 72 DOI: 10.1186/s12916-020-01516-x.
- 17 Witchel SF, Burghard AC, Tao RH, Oberfield SE. The diagnosis and treatment of PCOS in adolescents: an update. Curr Opin Pediatr 2019; 31 (04) 562-569 DOI: 10.1097/MOP.0000000000000778.
- 18 Morin-Papunen L. Risk factors in adolescence for the development of polycystic ovary syndrome. Gynakologe 2016; 49 (11) 838-845 DOI: 10.1007/s00129-016-3935-9.
- 19 Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L. et al; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 2018; 110 (03) 364-379 DOI: 10.1016/j.fertnstert.2018.05.004.
- 20 Milczarek M, Kucharska A, Borowiec A. Difficulties in diagnostics of polycystic ovary syndrome in adolescents - a preliminary study. Pediatr Endocrinol Diabetes Metab 2019; 25 (03) 122-126 DOI: 10.5114/pedm.2019.87177.
- 21 Dursun F, Güven A, Yıldız M. Assessment of anti-müllerian hormone level in management of adolescents with polycystic ovary syndrome. J Clin Res Pediatr Endocrinol 2016; 8 (01) 55-60 DOI: 10.4274/jcrpe.2338.
- 22 Khashchenko E, Uvarova E, Vysokikh M, Ivanets T, Krechetova L, Tarasova N. et al. The relevant hormonal levels and diagnostic features of polycystic ovary syndrome in adolescents. J Clin Med 2020; 9 (06) 1831 DOI: 10.3390/jcm9061831.
- 23 Asanidze E, Kristesashvili J, Pkhaladze L, Khomasuridze A. The value of anti-Mullerian hormone in the management of polycystic ovary syndrome in adolescents. Gynecol Endocrinol 2019; 35 (11) 974-977 DOI: 10.1080/09513590.2019.1616689.
- 24 Amr N, Abdel-Rahim HE. The effect of chromium supplementation on polycystic ovary syndrome in adolescents. J Pediatr Adolesc Gynecol 2015; 28 (02) 114-118 DOI: 10.1016/j.jpag.2014.05.005.
- 25 Javed A, Kumar S, Simmons PS, Lteif AN. Phenotypic characterization of polycystic ovary syndrome in adolescents based on menstrual irregularity. Horm Res Paediatr 2015; 84 (04) 223-230 DOI: 10.1159/000435883.
- 26 Zhu RY, Wong YC, Yong EL. Sonographic evaluation of polycystic ovaries. Best Pract Res Clin Obstet Gynaecol 2016; 37: 25-37 DOI: 10.1016/j.bpobgyn.2016.02.005.
- 27 Kenigsberg LE, Agarwal C, Sin S, Shifteh K, Isasi CR, Crespi R. et al. Clinical utility of magnetic resonance imaging and ultrasonography for diagnosis of polycystic ovary syndrome in adolescent girls. Fertil Steril 2015; 104 (05) 1302-9.e1 , 4
- 28 Barcellos CR, Rocha MP, Hayashida SA, Dantas WS, Dos Reis Vieira Yance V, Marcondes JA. Obesity, but not polycystic ovary syndrome, affects circulating markers of low-grade inflammation in young women without major cardiovascular risk factors. Hormones (Athens) 2015; 14 (02) 251-257 DOI: 10.14310/horm.2002.1584.
- 29 Çınar M, Aksoy RT, Güzel Aİ, Tokmak A, Çandar T, Taşçı Y. The predictive role of serum cystatin c levels in polycystic ovary syndrome in adolescents. J Pediatr Adolesc Gynecol 2016; 29 (04) 353-356 DOI: 10.1016/j.jpag.2015.12.005.
- 30 Ersoy AO, Tokmak A, Ozler S, Oztas E, Ersoy E, Celik HT. et al. Are progranulin levels associated with polycystic ovary syndrome and its possible metabolic effects in adolescents and young women?. Arch Gynecol Obstet 2016; 294 (02) 403-409 DOI: 10.1007/s00404-016-4096-8.
- 31 Pal Singh Kochar I, Ramachandran S, Sethi A. Metformin in adolescent PCOS: the way forward. Pediatr Endocrinol Rev 2017; 15 (02) 142-146 DOI: 10.17458/per.vol15.2017.prs.metforminadolescentpcos.
- 32 Pkhaladze L, Barbakadze L, Kvashilava N. Myo-inositol in the treatment of teenagers affected by PCOS. Int J Endocrinol 2016; 2016: 1473612 DOI: 10.1155/2016/1473612.
- 33 Abdolahian S, Tehrani FR, Amiri M, Ghodsi D, Yarandi RB, Jafari M. et al. Effect of lifestyle modifications on anthropometric, clinical, and biochemical parameters in adolescent girls with polycystic ovary syndrome: a systematic review and meta-analysis. BMC Endocr Disord 2020; 20 (01) 71 DOI: 10.1186/s12902-020-00552-1.
- 34 Wong JM, Gallagher M, Gooding H, Feldman HA, Gordon CM, Ludwig DS. et al. A randomized pilot study of dietary treatments for polycystic ovary syndrome in adolescents. Pediatr Obes 2016; 11 (03) 210-220 DOI: 10.1111/ijpo.12047.
- 35 Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE), Androgen Excess and PCOS Society (AES). American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome–part 1. Endocr Pract 2015; 21 (11) 1291-1300 DOI: 10.4158/EP15748.DSC.
- 36 Cirillo F, Catellani C, Lazzeroni P, Sartori C, Tridenti G, Vezzani C. et al. HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA). Gynecol Endocrinol 2020; 36 (07) 588-593 DOI: 10.1080/09513590.2020.1725967.